Cell Reprogramming for Drug Toxicology Assessment

iPSCs technology has proven to be a powerful method for predictive toxicology studies. Creative Bioarray is committed to helping customers use iPSC technology to generate certain cell types that cannot be obtained from actual humans, such as in cardiotoxicity, hepatotoxicity, and neurotoxicity. Our specialized solutions will greatly accelerate our clients' research projects in toxicology evaluation.


Since new compounds may cause toxic damage in various tissues and organs, developing suitable 2D or 3D cultured cell models for toxicity testing at an early stage is a critical step in drug development. In previous studies, mouse embryonic stem cell (mESCs) test have been widely used by the pharmaceutical industry to assess the genotoxicity, cytotoxicity, and inhibition of spontaneous differentiation of mESCs into beating embryoid bodies (EBs) of drug compounds. However, species-specific pharmacokinetics limits the ability of the assay to predict the drug toxicity profile of human diseases.

In addition to its potential use in drug screening, the hiPSCs technique can be a powerful tool for toxicological assessment studies. In order to avoid species differences, researchers have suggested that combining hiPSCs with molecular methods is an appropriate strategy for toxicological evaluation. In addition, the generation of iPSCs from patients exhibiting idiosyncratic responses to drugs may help to screen for relatively rare but severe toxic effects. In conclusion, patient-specific iPSCs could provide a powerful new tool for personalized medicine.

Fig 1. Generation and utilization of human iPSCs in predictive toxicology.Fig.1 Generation and utilization of human iPSCs in predictive toxicology. (Anson, 2011)

Solutions for Drug Toxicology Assessment based on Cell Reprogramming

Cell Reprogramming for Drug Toxicology Assessment

Currently, Researchers at Creative Bioarray have been able to prepare disease-specific and normal population iPSCs in large quantities. Therefore we can provide researchers with unlimited quantities of stable quality iPSCs to test drug toxicity in vitro, thus avoiding the harm of drug toxicity to patients in Phase I clinical trials. The solutions we offer include but are not limited to:

  • iPSCs-based Hepatotoxicity Assessment
  • We are committed to helping customers generate hiPSC-derived hepatocytes to develop sensitive and reproducible screening tools for the assessment of hepatotoxicity.

  • iPSCs-based Cardiotoxicity Assessment
  • We are dedicated to providing clients with specialized solutions for generating human iPSC-derived cardiomyocytes (hiPSC-CMs) to assess cardiotoxicity/safety during drug development.

  • iPSCs-based Neuronal Toxicity Assessment
  • We help our clients assess neuronal toxicity by generating iPSC-derived neurons and building in vitro models to better explain human neurotoxic responses and to screen drug candidates.


  • First-class cell reprogramming platform
  • Providing detailed toxicity reports including raw data and images
  • Flexible solutions that can be adapted to customer requirements
  • Detailed after-sales service

Based on its many years of experience, Creative Bioarray can provide customers with drug toxicity testing services based on cell reprogramming technology, including liver toxicity, cardiotoxicity and neuronal toxicity. If you need services in drug toxicity testing, please feel free to contact us and we will answer and serve you immediately.


  1. Anson, B.D.; et al. Opportunities for use of human iPS cells in predictive toxicology. Clinical pharmacology and therapeutics. 2011, 89(5):754-758.
For Research Use Only. Not For Clinical Use.